Headlines about Oramed Pharmaceuticals (NASDAQ:ORMP) have trended positive recently, Accern reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oramed Pharmaceuticals earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.9865900263817 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

ORMP has been the subject of several research reports. HC Wainwright set a $25.00 target price on Oramed Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 22nd. ValuEngine upgraded Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th.

Shares of Oramed Pharmaceuticals (NASDAQ ORMP) traded up 0.0260% on Tuesday, hitting $9.6025. The stock had a trading volume of 27,117 shares. The firm’s 50-day moving average is $8.38 and its 200 day moving average is $7.63. The stock’s market cap is $127.91 million. Oramed Pharmaceuticals has a 1-year low of $5.70 and a 1-year high of $10.00.

In related news, Director Xiaopeng Li acquired 89,636 shares of the stock in a transaction dated Wednesday, August 2nd. The shares were bought at an average cost of $8.50 per share, for a total transaction of $761,906.00. Following the purchase, the director now owns 206,350 shares in the company, valued at approximately $1,753,975. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 27.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/19/favorable-press-coverage-somewhat-unlikely-to-affect-oramed-pharmaceuticals-ormp-share-price.html.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Insider Buying and Selling by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Stock Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.